Published in JAMA on June 16, 2010
Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis | NCT01509339
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med (2014) 2.15
Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med (2012) 2.03
Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev (2015) 1.94
Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros (2011) 1.41
Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother (2011) 1.26
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax (2013) 1.06
Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med (2011) 0.97
Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis (2012) 0.96
Clinical applications of pulmonary delivery of antibiotics. Adv Drug Deliv Rev (2014) 0.93
Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol (2012) 0.92
Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc (2014) 0.92
Reactive oxygen species, apoptosis, antimicrobial peptides and human inflammatory diseases. Pharmaceuticals (Basel) (2015) 0.91
Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother (2011) 0.91
Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt) (2014) 0.91
Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections. Clin Microbiol Rev (2016) 0.89
The Microbiome in Cystic Fibrosis. Clin Chest Med (2015) 0.89
Children and young adults with CF in the USA have better lung function compared with the UK. Thorax (2014) 0.86
Antibiotic and anti-inflammatory therapies for cystic fibrosis. Cold Spring Harb Perspect Med (2013) 0.84
Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data. Eur J Health Econ (2014) 0.84
Cystic fibrosis chronic rhinosinusitis: a comprehensive review. Am J Rhinol Allergy (2013) 0.83
Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient. J Pediatr Pharmacol Ther (2014) 0.82
Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients. BMC Pulm Med (2015) 0.81
Prevention and treatment of Staphylococcus aureus biofilms. Expert Rev Anti Infect Ther (2015) 0.79
Cystic Fibrosis: Microbiology and Host Response. Pediatr Clin North Am (2016) 0.78
Emergence of cfr-Mediated Linezolid Resistance in a Methicillin-Resistant Staphylococcus aureus Epidemic Clone Isolated from Patients with Cystic Fibrosis. Antimicrob Agents Chemother (2015) 0.77
Throat Swabs and Sputum Culture as Predictors of P. aeruginosa or S. aureus Lung Colonization in Adult Cystic Fibrosis Patients. PLoS One (2016) 0.77
Update on Epidemiology and Treatment of MRSA Infections in Children. Curr Pediatr Rep (2013) 0.77
Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience. Clin Respir J (2011) 0.77
Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis. PLoS One (2015) 0.77
Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis. J Cyst Fibros (2016) 0.77
Outcomes and Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Differs by Staphylococcal Cassette Chromosome mec (SCCmec) Type in Children With Cystic Fibrosis. J Pediatric Infect Dis Soc (2014) 0.76
Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiol (2015) 0.76
In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia. Antimicrob Agents Chemother (2011) 0.75
Biomarkers for cystic fibrosis drug development. J Cyst Fibros (2016) 0.75
MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis. ERJ Open Res (2016) 0.75
Bactericidal Effect of Tomatidine-Tobramycin Combination against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Is Enhanced by Interspecific Small-Molecule Interactions. Antimicrob Agents Chemother (2015) 0.75
Detection of methicillin-resistant Staphylococcus aureus in clinical specimens from cystic fibrosis patients by use of chromogenic selective agar. J Clin Microbiol (2012) 0.75
Background and Epidemiology. Pediatr Clin North Am (2016) 0.75
Molecular epidemiology of methicillin-resistant Staphylococcus aureus isolated in serial cultures from the respiratory tract of children with cystic fibrosis. Pediatr Infect Dis J (2014) 0.75
Lung Microbiota and Its Impact on the Mucosal Immune Phenotype. Microbiol Spectr (2017) 0.75
Evaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients. J Pediatr Pharmacol Ther (2016) 0.75
Ralstonia mannitolilytica in cystic fibrosis: A new predictor of worse outcomes. Respir Med Case Rep (2016) 0.75
The Dynamics of Disease Progression in Cystic Fibrosis. PLoS One (2016) 0.75
Methicillin-resistant Staphylococcus aureus acquisition in healthcare workers with cystic fibrosis: a retrospective cross-sectional study. BMC Pulm Med (2016) 0.75
Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis. BMC Pulm Med (2015) 0.75
Influenza vaccination in children at high risk of respiratory disease. Ther Adv Vaccines (2013) 0.75
Air pollution exposure is associated with MRSA acquisition in young U.S. children with cystic fibrosis. BMC Pulm Med (2017) 0.75
D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung Infection. Front Chem (2017) 0.75
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2011) 2.84
Safety and feasibility of interventional pulmonologists performing bedside percutaneous endoscopic gastrostomy tube placement. Chest (2013) 2.69
In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med (2003) 2.64
Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med (2008) 2.63
Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest (2003) 2.54
Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol (2011) 2.48
Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration (2005) 2.43
Multiple norovirus infections in a birth cohort in a Peruvian Periurban community. Clin Infect Dis (2013) 2.37
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med (2012) 2.36
Beyond mortality: future clinical research in acute lung injury. Am J Respir Crit Care Med (2010) 2.28
An oversized allograft is associated with improved survival after lung transplantation for idiopathic pulmonary arterial hypertension. J Heart Lung Transplant (2013) 2.13
Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.03
The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS (2013) 1.92
Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med (2002) 1.88
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A (2009) 1.86
The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol (2002) 1.85
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol (2010) 1.71
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.70
Impact of the lung allocation score on resource utilization after lung transplantation in the United States. J Heart Lung Transplant (2010) 1.67
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol (2002) 1.67
Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol (2007) 1.67
Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol (2004) 1.65
A randomized prospective trial of the utility of rapid on-site evaluation of transbronchial needle aspirate specimens. J Bronchology Interv Pulmonol (2011) 1.64
The value of positive end-expiratory pressure and Fio₂ criteria in the definition of the acute respiratory distress syndrome. Crit Care Med (2011) 1.64
Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol (2004) 1.64
Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med (2006) 1.63
Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr (2008) 1.60
Lung size mismatch and survival after single and bilateral lung transplantation. Ann Thorac Surg (2013) 1.54
The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials (2009) 1.54
Addressing geographical variation in the progression of non-communicable diseases in Peru: the CRONICAS cohort study protocol. BMJ Open (2012) 1.52
A simple classification model for hospital mortality in patients with acute lung injury managed with lung protective ventilation. Crit Care Med (2011) 1.52
Distraction therapy with nature sights and sounds reduces pain during flexible bronchoscopy: a complementary approach to routine analgesia. Chest (2003) 1.51
Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2014) 1.50
An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope (2010) 1.49
Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc (2007) 1.49
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol (2007) 1.46
Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther (2002) 1.45
Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.44
Epidemiologic differences between cyclosporiasis and cryptosporidiosis in Peruvian children. Emerg Infect Dis (2002) 1.43
Lung transplantation in older patients with cystic fibrosis: analysis of UNOS data. J Heart Lung Transplant (2009) 1.43
Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros (2011) 1.41
Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease. Am J Respir Cell Mol Biol (2006) 1.39
A case for vaccination. Am J Med (2007) 1.39
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros (2009) 1.35
Wasting is associated with stunting in early childhood. J Nutr (2012) 1.33
Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr (2009) 1.31
Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol (2008) 1.30
Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med (2007) 1.29
Tobacco use and nicotine dependence among HIV-infected and uninfected injection drug users. Addict Behav (2010) 1.27
Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother (2011) 1.26
Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest (2007) 1.25
Lack of an adverse effect of Giardia intestinalis infection on the health of Peruvian children. Am J Epidemiol (2008) 1.24
Survival after single versus bilateral lung transplantation for high-risk patients with pulmonary fibrosis. Ann Thorac Surg (2009) 1.22
Diarrhea in early childhood: short-term association with weight and long-term association with length. Am J Epidemiol (2013) 1.22
Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta (2006) 1.22
Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res (2011) 1.21
Effect of urbanisation on asthma, allergy and airways inflammation in a developing country setting. Thorax (2011) 1.20
The impact of center volume on survival in lung transplantation: an analysis of more than 10,000 cases. Ann Thorac Surg (2009) 1.20
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol (2007) 1.19
Household food access and child malnutrition: results from the eight-country MAL-ED study. Popul Health Metr (2012) 1.18
The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest (2007) 1.18
Association of operative time of day with outcomes after thoracic organ transplant. JAMA (2011) 1.16
Complications from recruitment maneuvers in patients with acute lung injury: secondary analysis from the lung open ventilation study. Respir Care (2012) 1.16
Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax (2011) 1.16
The effect of lung size mismatch on complications and resource utilization after bilateral lung transplantation. J Heart Lung Transplant (2012) 1.15
Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection. J Immunol (2008) 1.15
Myocardial delayed enhancement in pulmonary hypertension: pulmonary hemodynamics, right ventricular function, and remodeling. AJR Am J Roentgenol (2011) 1.15
Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med (2009) 1.15
Global Noncommunicable Disease Research: Opportunities and Challenges. Ann Intern Med (2015) 1.15
HIV infection in the etiology of lung cancer: confounding, causality, and consequences. Proc Am Thorac Soc (2011) 1.13
Lung allocation score predicts survival in lung transplantation patients with pulmonary fibrosis. Ann Thorac Surg (2009) 1.13
The impact of recipient body mass index on survival after lung transplantation. J Heart Lung Transplant (2010) 1.13
Computerized lung sound analysis as diagnostic aid for the detection of abnormal lung sounds: a systematic review and meta-analysis. Respir Med (2011) 1.12
Donor-recipient size matching and survival after lung transplantation. A cohort study. Ann Am Thorac Soc (2013) 1.09
Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med (2002) 1.08
OBSTRUCTIVE LUNG DISEASE AND EXPOSURE TO BURNING BIOMASS FUEL IN THE INDOOR ENVIRONMENT. Glob Heart (2012) 1.07
Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. BMC Pulm Med (2010) 1.06
Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii Pneumonia in the United States (1986 to 2005). Chest (2009) 1.06
Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros (2014) 1.06
Insurance status is an independent predictor of long-term survival after lung transplantation in the United States. J Heart Lung Transplant (2011) 1.04
Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther (2007) 1.04
Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD (2011) 1.04
Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation. J Control Release (2011) 1.03
A pipeline of therapies for cystic fibrosis. Semin Respir Crit Care Med (2009) 1.03
Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosis. J Med Genet (2006) 1.02
Chronic exposure to biomass fuel is associated with increased carotid artery intima-media thickness and a higher prevalence of atherosclerotic plaque. Heart (2013) 1.01
Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) (2011) 1.01